• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by PROCEPT BioRobotics Corporation (Amendment)

    5/7/24 9:45:23 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care
    Get the next $PRCT alert in real time by email
    SC 13D/A 1 ef20028618_sc13da.htm SC 13D/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D
    Under the Securities Exchange Act of 1934
    (Amendment No. 5)*
     
    PROCEPT BioRobotics Corporation
    (Name of Issuer)
     
    Common Stock, par value $0.00001 per share
    (Title of Class of Securities)
     
    74276L105
    (CUSIP Number)
     
    John Bateman
    CPMG, Inc.
    4215 West Lovers Ln, Suite 100
    Dallas, Texas 75209
    214-871-6816
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     
    May 3, 2024
    (Date of Event which Requires Filing of this Statement)
     
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP NO. 74276L105
    Page 2 of 7 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    CPMG, INC.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    AF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Texas
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    3,222,345
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    3,222,345
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    3,222,345
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    6.3%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     


    CUSIP NO. 74276L105
    Page 3 of 7 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    R. KENT MCGAUGHY, JR.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    AF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    4,523
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    3,775,937
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    4,523
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    3,775,937
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    3,780,460
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    7.4%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN, HC
     
     
     
     


    CUSIP NO. 74276L105
    Page 4 of 7 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    ANTAL ROHIT DESAI
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    PF, AF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    130,117 (1)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    3,438,668
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    130,117 (1)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    3,438,668
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    3,568,785 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    6.9%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN, HC
     
     
     
     

    (1) This amount includes 72,442 Shares (as defined herein) that are obtainable upon exercise of options granted to the Reporting Person.


    CUSIP NO. 74276L105
    Page 5 of 7 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    WHITE TAILED PTARMIGAN, LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Texas
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    2,823,681
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    2,823,681
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    2,823,681
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    5.5%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     


    CUSIP NO. 74276L105
    Page 6 of 7 Pages
    Item 1.
    Security and Issuer
     
    Item 1 of the Schedule 13D is hereby amended by adding the following:
     
    This Amendment No. 5 to Schedule 13D (“Amendment No. 5”) is being filed by the undersigned, pursuant to §240.13d-2(a), with respect to the Common Stock, $0.00001 par value per share (the “Shares”), of PROCEPT BioRobotics Corporation (the “Issuer” or the “Company”), whose principal executive offices are located at 150 Baytech Drive, San Jose, California 95134. This Amendment No. 5 amends and supplements the Schedule 13D filed by the Reporting Persons with the U.S. Securities and Exchange Commission (the “SEC”) on September 27, 2021, as amended by Amendment No. 1 filed with the SEC on September 8, 2022, Amendment No. 2 filed with the SEC on September 13, 2022, Amendment No. 3 filed with the SEC on November 16, 2022, and Amendment No. 4 filed with the SEC on December 7, 2022 (collectively, “the Schedule 13D”). Except as specifically provided herein, this Amendment No. 5 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used but not defined in this Amendment No. 5 shall have the meanings given to them in the Schedule 13D.
     
    Item 5.
    Interest in Securities of the Issuer
     
    Item 5 of the Schedule 13D is hereby amended by adding the following:
     
    (a, b) As of the date hereof, CPMG may be deemed to be the beneficial owner of 3,222,345 Shares (approximately 6.3% of the total number of Shares outstanding). This amount includes: (i) 2,823,681 Shares held for the account of WTP; (ii) 344,627 Shares held for the account of Mallard Fund; and (iii) 54,037 Shares held for the account of Kestrel Fund. CPMG is the general partner and investment manager of each of WTP, Mallard Fund and Kestrel Fund.
     
    As of the date hereof, Mr. McGaughy may be deemed to be the beneficial owner of 3,780,460 Shares (approximately 7.4% of the total number of Shares outstanding). This amount includes: (i) 3,222,345 Shares beneficially owned by CPMG; (ii) 553,592 Shares held by Lagos Trust, of which Mr. McGaughy is trustee and has shared voting and dispositive control with his spouse; and (iii) 4,523 Shares held directly by Mr. McGaughy.
     
    As of the date hereof, Mr. Desai may be deemed to be the beneficial owner of 3,568,785 Shares (approximately 6.9% of the total number of Shares outstanding). This amount includes: (i) 3,222,345 Shares beneficially owned by CPMG; (ii) 57,675 Shares held directly by Mr. Desai; (iii) 216,323 Shares held by The 2:22 DNA Trust; and (iv) 72,442 Shares that are obtainable upon exercise of options granted to Mr. Desai.
     
    As of the date hereof, WTP may be deemed the beneficial owner of 2,823,681 Shares (approximately 5.5% of the total number of Shares outstanding) held for its account.
     
    Each of the Reporting Persons exercises shared voting power and shared dispositive power over the 2,823,681 Shares held for the account of WTP. CPMG, Mr. McGaughy and Mr. Desai exercise shared voting power and shared dispositive power over the 344,627 Shares held for the account of Mallard Fund and the 54,037 Shares held for the account of Kestrel Fund. Mr. McGaughy and his spouse exercise shared voting power and shared dispositive power over the 553,592 Shares held by Lagos Trust. Mr. McGaughy exercises sole voting power and sole dispositive power over the 4,523 Shares he holds directly. Mr. Desai and his spouse exercise shared voting power and shared dispositive power over the 216,323 Shares held by The 2:22 DNA Trust. Mr. Desai exercises sole voting power and sole dispositive power over the 57,675 Shares he holds directly and the 72,442 Shares that are obtainable upon exercise of options granted to Mr. Desai.
     
    The beneficial ownership percentages reported herein were calculated in accordance with Rule 13d-3(d)(1)(i) and are based on (i) 51,424,151 Shares outstanding as of April 29, 2024, as reported in the Issuer’s quarterly report on Form 10-Q filed with the SEC on May 2, 2024, and, for Mr. Desai, (ii) the 72,442 Shares Mr. Desai has the right to acquire upon exercise of options.
     
    (c) On May 3, 2024, WTP made an in-kind distribution of  2,206,188 Shares on a pro-rata basis, for no consideration, of which: (i) Mallard Fund received 86,157 Shares; (ii) Kestrel Fund received 13,509 Shares; (iii) Lagos Trust received  211,446 Shares; (iv) The 2:22 DNA Trust received 108,737 Shares; (v) Mr. McGaughy received 1,131 Shares; and (vi) Mr. Desai received 81 Shares. Except for transactions reported herein, there have been no transactions in the Shares by the Reporting Persons in the past sixty days.
     
    (d) No person(s) other than the Reporting Persons is known to have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares beneficially owned by the Reporting Persons.
     
    (e) This Item 5(e) is not applicable.


    CUSIP NO. 74276L105
    Page 7 of 7 Pages
    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

       
    CPMG, INC.
     
           
     
    By:
    /s/ John Bateman
     
       
    Name: 
    John Bateman
     
       
    Title:
    Chief Operating Officer
     
             
       
    R. KENT MCGAUGHY, JR.
     
             
       
    /s/ R. Kent McGaughy, Jr.
     
             
       
    ANTAL ROHIT DESAI
     
             
       
    /s/ Antal Rohit Desai
     

       
    WHITE TAILED PTARMIGAN, LP
     
           
     
    By:
    CPMG, Inc., its General Partner
     
           
     
    By:
    /s/ John Bateman
     
       
    Name:  
    John Bateman
     
       
    Title:
    Chief Operating Officer
     
             
    May 7, 2024
           

    Attention: Intentional misstatements or omissions of fact constitute federal violations (see 18 U.S.C. 1001)



    Get the next $PRCT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRCT

    DatePrice TargetRatingAnalyst
    12/2/2024$105.00Overweight
    Morgan Stanley
    11/14/2024$95.00Hold
    Jefferies
    8/11/2023$42.00Overweight
    Piper Sandler
    5/31/2023Outperform
    William Blair
    10/31/2022Neutral
    BTIG Research
    10/25/2022$58.00Buy
    Truist
    9/2/2022$49.00Overweight
    Wells Fargo
    7/15/2022$47.00Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $PRCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley initiated coverage on PROCEPT BioRobotics with a new price target

      Morgan Stanley initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $105.00

      12/2/24 7:01:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • Jefferies initiated coverage on PROCEPT BioRobotics with a new price target

      Jefferies initiated coverage of PROCEPT BioRobotics with a rating of Hold and set a new price target of $95.00

      11/14/24 8:28:45 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • Piper Sandler initiated coverage on PROCEPT BioRobotics with a new price target

      Piper Sandler initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $42.00

      8/11/23 7:19:06 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care

    $PRCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, CEO Zadno Reza sold $312,404 worth of shares (5,475 units at $57.06), decreasing direct ownership by 3% to 173,070 units (SEC Form 4)

      4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

      3/19/25 4:16:41 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • EVP, CFO Waters Kevin sold $41,825 worth of shares (733 units at $57.06), decreasing direct ownership by 0.67% to 107,991 units (SEC Form 4)

      4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

      3/19/25 4:15:38 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • EVP, Chief Comm. Officer Shiblaq Hisham sold $14,094 worth of shares (247 units at $57.06), decreasing direct ownership by 0.39% to 63,133 units (SEC Form 4)

      4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

      3/19/25 4:08:29 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care

    $PRCT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June

      SAN JOSE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that members of management will present at four upcoming investor conferences in May and June. 2025 Bank of America Health Care Conference Location – Las Vegas, NVFireside Chat – Wednesday, May 14 at 3pm PT / 6pm ET 45th Annual William Blair Growth Stock Conference Location – Chicago, ILPresentation – Wednesday, June 4 at 10am CT / 11am ET 2025 Jefferies Global Healthcare Conference Location – New York City, NYFireside Chat – Thursday, June 5 at 8:45m ET

      4/29/25 4:03:00 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops

      Presentations underscore long-term clinical outcomes, safety and durability in BPH treatment Attendees invited to experience hands-on HYDROS Robotic System demonstrations SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT)  ("PROCEPT"), a surgical robotics company whose mission is to revolutionize BPH treatment globally, today announced an extensive lineup of scientific presentations and interactive workshops at the 2025 American Urological Association (AUA) Annual Meeting, taking place April 26–29 in Las Vegas, Nevada. Clinical data presentations will highlight long-term outcomes, safety and durability of Aquablation® therapy for BPH. Th

      4/24/25 4:03:00 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

      SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2025. Recent Highlights Total revenue of $69.2 million for the first quarter of 2025, an increase of 55% compared to the prior year period in 2024U.S. handpiece and consumables revenue of 38.0 million for the first quarter of 2025, an increase of 61% compared to the prior year period in 2024Sold 43 new robotic sy

      4/24/25 7:00:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care

    $PRCT
    Leadership Updates

    Live Leadership Updates

    See more
    • Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

      SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th

      10/28/24 7:00:00 AM ET
      $ISRG
      $PRCT
      $SNBR
      $SWAV
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
      Home Furnishings
    • Jupiter Endovascular Exits Stealth With $21M in New Financing to Fund Pivotal Trial for Pulmonary Embolism

      Carl J. St. Bernard Appointed as Chief Executive Officer Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions, announced today that it has exited stealth mode with a $21 million new round of financing. Sonder Capital was a key participant in the round that included participation from multiple strategic investors. The funding will be used to support the company's upcoming pivotal trial for Pulmonary Embolism and development of additional clinical applications of the Endoportal ControlTM technology. "For decades, the

      8/15/24 10:00:00 AM ET
      $ISRG
      $PRCT
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • Sonder Capital Appoints Kate Garrett as Managing Partner to Lead Next Generation of Growth

      Co-founders and industry luminaries Dr. Fred Moll and Jay Watkins will assume the newly created role of Co-chair as firm closes its latest fund, Futures II Sonder Capital, a leading venture capital firm focused on identifying teams and technologies that will transform healthcare, today announced the appointment of firm Co-founder Kate Garrett as Managing Partner. In this pivotal role, Garrett will spearhead Sonder's next phase of growth as the firm closes Sonder Futures II, its second early stage fund. With Garrett becoming Managing Partner, Sonder Co-founders and industry luminaries Fred Moll, M.D. and Jay Watkins will maintain their roles as partners and assume the newly created posit

      4/2/24 8:00:00 AM ET
      $ISRG
      $PRCT
      $SWAV
      Industrial Specialties
      Health Care
      Medical/Dental Instruments

    $PRCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

      SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

      11/14/24 1:28:32 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

      SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

      11/12/24 5:01:10 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

      SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

      11/4/24 1:31:19 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care

    $PRCT
    Financials

    Live finance-specific insights

    See more
    • PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

      SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2025. Recent Highlights Total revenue of $69.2 million for the first quarter of 2025, an increase of 55% compared to the prior year period in 2024U.S. handpiece and consumables revenue of 38.0 million for the first quarter of 2025, an increase of 61% compared to the prior year period in 2024Sold 43 new robotic sy

      4/24/25 7:00:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting in Las Vegas, Nevada

      SAN JOSE, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Venetian Hotel in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time. Members of PROCEPT BioRobotics' management team presenting include: Reza Zadno – Chief Executive OfficerKevin Waters – Chief Financial OfficerSham Shiblaq – Chief Commercial OfficerBarry Templin – Chief Technology Officer Clinical perspectives will also be

      3/14/25 8:00:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics® Reports Fourth Quarter and Full Year 2024 Results

      SAN JOSE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the fourth quarter and year ended December 31, 2024. Recent Highlights Total revenue of approximately $68.2 million for the fourth quarter of 2024, an increase of 57% compared to the prior year periodU.S. system revenue of $27.6 million for the fourth quarter of 2024, an increase of 67% compared to the prior year periodSold 60 new robotic systems in the U.S. in the fourth quarter of 2024 at a blended average selling price of a

      2/25/25 4:02:00 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care

    $PRCT
    SEC Filings

    See more
    • SEC Form 10-Q filed by PROCEPT BioRobotics Corporation

      10-Q - PROCEPT BioRobotics Corp (0001588978) (Filer)

      5/2/25 4:51:16 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by PROCEPT BioRobotics Corporation

      DEFA14A - PROCEPT BioRobotics Corp (0001588978) (Filer)

      4/25/25 4:28:36 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by PROCEPT BioRobotics Corporation

      DEF 14A - PROCEPT BioRobotics Corp (0001588978) (Filer)

      4/25/25 4:26:51 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care